Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app tame OCD? scientists investigate digital mindfulness

NCT ID NCT07701616

Disease control Sponsor: Central South University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 21, 2026 · Updated 5 times

Summary

This study tests whether a 6-week digital mindfulness program, delivered through a mobile app, can help people with obsessive-compulsive disorder (OCD) manage their symptoms. The trial compares the digital therapy alone, standard medication alone, and a combination of both in 150 participants. Researchers will also measure brain activity and heart rate to understand how the therapy works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a digital mindfulness-based therapy program delivered via a mobile app
What this could lead to
If successful, this could offer a scalable, accessible treatment option for obsessive-compulsive disorder that reduces symptoms without the side effects of medication.
What could go wrong
This is a relatively small, early-stage trial, and the digital therapy may not be as effective as in-person treatment. Results may not apply to all people with OCD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. A primary diagnosis of obsessive-compulsive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 2. Aged 12 to 65 years. 3. Primary school education or above and able to understand the study procedures and complete the required assessments. 4. Willing and able to provide written informed consent. For participants under 18 years of age, written informed consent will also be obtained from a parent or legal guardian. 5. Participants who are already receiving psychotropic medication must have maintained a stable medication regimen for at least 4 weeks before enrollment. Any clinically necessary medication changes during the study will be documented. Exclusion Criteria: 1. Current or lifetime diagnosis of schizophrenia spectrum disorder, bipolar disorder, substance use disorder, or personality disorder. 2. Severe physical illness or central nervous system disease that may interfere with participation in the study. 3. Severe suicidal ideation or suicidal behavior within the past month. 4. Pregnancy, planned pregnancy, or breastfeeding. 5. Concurrent participation in another psychotherapy program or clinical trial. 6. Mindfulness practice within the past month. 7. Inability to understand or comply with the study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obsessive-compulsive disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obsessive-compulsive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obsessive-compulsive disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Second Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.